Lotus Pharmaceutical Co., Ltd. · TWSE:1795
Lotus Pharmaceutical — Q1 2025 Earnings Presentation
17 slides from Lotus Pharmaceutical's earnings presentation, May 21, 2025
Slide 1: Lotus Pharmaceutical 1Q25 Financial result
Lotus Pharmaceutical 1Q25 Financial result May 21, 2025
Slide 2: Safe Harbor Statement
INTRODUCTION LOTUS CONFIDENTIAL 2 Safe Harbor Statement Except for historical information contained herein, the matters set forth in this presentation are forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These forward lookin
Slide 3: Agenda
LOTUS CONFIDENTIAL 3 Agenda 1. 1Q25 BUSINESS HIGHLIGHTS 2. 1Q25 FINANCIAL RESULTS 3. LOTUS BUSINESS OUTLOOK
Slide 4: Business Highlights
01 BUSINESS HIGHLIGHTS
Slide 5: 1Q25 Results and Business Highlights
LOTUS CONFIDENTIAL 5 1Q25 RESULTS AND BUSINESS HIGHLIGHTS New First Quarter Record Results ➢ Revenue TWD 4,730 mn (13% YoY) and EPS TWD 5.47 (38% YoY), both setting new 1Q records • Gross margin of 61.6%, 6.7ppt improvement from last year supported by contribution from higher-margin oncology export
Slide 6: YTD Pipeline Updates
LOTUS CONFIDENTIAL 6 YTD PIPELINE UPDATES Key Licensing Key Filings Key Approvals Key Launches Agreements • Voclosporin (US) – • Adcirca(TW) - the first and • Alpha Choay (Vietnam) • Serplulimab(Anti-PD-1 mAb), Successful NCE-1 filing only class I ERA therapy an orphan drug for small cell • Darbepoe
Slide 7: YTD Pipeline Summary - R&D and BD
LOTUS CONFIDENTIAL 7 YTD PIPELINE SUMMARY - R&D and BD R&D Pipelines - 30 BD Pipelines - 35 Oncology & Immunology 18 15 Central Nervous System 2 5 Primary Care & Lifestyle* 9 14 Nephrology 1 1 *Primary Care & Lifestyle: Anti-obesity, Cardiovascular, Respiratory & Allergy, Endocrinology & Diabetes, O
Slide 8: YTD Pipeline Summary - R&D
BUSINESS STRATEGY LOTUS CONFIDENTIAL 8 YTD PIPELINE SUMMARY - R&D Product Type in RD Pipelines Pipeline highlights FTF Day1 505b2 ➢ 30 ongoing projects ➢ 11 FTFs, 13 Day 1 and 6 505b(2) 20% ➢ Co-development agreements with 43% partners with unique technology and/or IPs ➢5 new projects initiated ➢ 1
Slide 9: YTD Pipeline Summary - BD
BUSINESS STRATEGY LOTUS CONFIDENTIAL 9 YTD PIPELINE SUMMARY - BD Product Type in BD Pipelines Pipeline highlights Gx NCE 505b2 Biosimilars Tail-end brand ➢ 35 high-value, branded innovative products ➢ 18 NCEs, 3 505b(2) ,4 biosimilars, 3 9% branded, 7 generics 51% ➢ Hybrid Strategy 11% ➢ BD expands
Slide 10: Financial Information
02 FINANCIAL INFORMATION
Slide 11: 1Q25 Financial Results
LOTUS CONFIDENTIAL 11 1Q25 Financial Results (in NTD millions, except for EPS) Key Financials 1Q25 Performance 25'Q1 YoY Change Net Sales 4,730 12.7% • Net sales increased 12.7% YoY driven by lenalidomide US Cost of Goods (1,814) -4.2% sales, robust growth of SEA market by successful integration Gro
Slide 12: 1Q25 Sales Expansion YoY
LOTUS CONFIDENTIAL 12 1Q25 Sales Expansion YoY +13% YoY NT$4,730mn 451 NT$4,198mn -195 327 7 24 -83 z z +12% YoY +14% YoY 1Q24 KR TW SEA RoA US RoW 1Q25
Slide 13: Diversification Across Therapies and Markets
LOTUS CONFIDENTIAL 13 Diversification Across Therapies and Markets Diversified Portfolio Revenue Breakdown 1Q25 Revenue Breakdown by TA Primary Care Export 25% & Lifestyle Business 41% Women 45% 45% Central 6% Healthcare US Nervous 14% System 5% Nephrology 4% RoW Export-Gx 1% RoA 9% Branded-Gx SEA A
Slide 14: Strong Capital Structure
LOTUS CONFIDENTIAL 14 Strong Capital Structure LTM EBITDA* (NT$mn) NET DEBT/LTM EBITDA* LTM EBITDA Margin(%) 8,303 43 1.35 37 6,075 0.79 1Q24 1Q25 1Q24 1Q25 1Q24 1Q25 *EBITDA =EBIT + Depreciation + Amortization + Impairment + Shared Based Payment
Slide 15: Business Outlook
03 “tank BUSINESS OUTLOOK
Slide 16: Update On Recent US Market Developments
LOTUS CONFIDENTIAL 16 Update On Recent US Market Developments US Tariffs Risks Impact remains unclear due to ongoing shifts of tariff policies Completed early stockpiling of inventories in US warehouses since April Management to continue closely monitor latest development and enhance readiness for p
Slide 17: An international pharmaceutical company with global presence
An international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines https://www.lotuspharm.com.tw/ +886 2 2700 5908 info@lotuspharm.com in www.linkedin.com/company/lotus-pharmaceutica